Severe agranulocytosis in a patient with metastatic non-small-cell lung cancer treated with nivolumab

Lung Cancer

Volumn 99, Issue , 2016, Pages 123-126

  Tabchi, Samer ^a   Weng, Xiaoduan ^a   Blais, Normand ^a  

^a CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

Agranulocytosis; Immune checkpoint inhibitors; Immune mediated adverse events; Neutropenia; Nivolumab

Indexed keywords

ANTIBIOTIC AGENT; CISPLATIN; CORTICOSTEROID; COTRIMOXAZOLE; FILGRASTIM; IMMUNOGLOBULIN; MESALAZINE; METHYLPREDNISOLONE; NIVOLUMAB; PEMETREXED; PREDNISONE; IMMUNOLOGICAL ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

AGED; AGRANULOCYTOSIS; ANAPLASTIC LYMPHOMA KINASE GENE; ARTICLE; BIOPSY; BLOOD CELL COUNT; BLOOD CULTURE; BONE LESION; CANCER CHEMOTHERAPY; CASE REPORT; CERVICAL LYMPHADENOPATHY; COMPUTER ASSISTED TOMOGRAPHY; CORTICOSTEROID THERAPY; DISEASE COURSE; DRUG MEGADOSE; DRUG WITHDRAWAL; ECTHYMA; EPIDERMAL GROWTH FACTOR RECEPTOR GENE; FEMALE; GENE; HOSPITALIZATION; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER DISEASE; LIVER FUNCTION TEST; LUNG ADENOCARCINOMA; LYMPHADENOPATHY; MEDIASTINUM LYMPH NODE; METASTATIC NON SMALL CELL LUNG CANCER; MYELOID PROGENITOR CELL; NEUTROPENIA; NEUTROPHIL COUNT; NON SMALL CELL LUNG CANCER; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SKIN DEFECT; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION; THORAX RADIOGRAPHY; TREATMENT RESPONSE; BONE MARROW; CANCER STAGING; COMPLICATION; HEALTH STATUS INDICATOR; LEUKOCYTE COUNT; LUNG TUMOR; METASTASIS; PATHOLOGY;

AGED; AGRANULOCYTOSIS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS, IMMUNOLOGICAL; BONE MARROW; CARCINOMA, NON-SMALL-CELL LUNG; ECTHYMA; FEMALE; HEALTH STATUS INDICATORS; HUMANS; LEUKOCYTE COUNT; LIVER FUNCTION TESTS; LUNG NEOPLASMS; NEOPLASM METASTASIS; NEOPLASM STAGING;

EID: 84978829280     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2016.06.026     Document Type: Article

References (19)

1. [1] Yun, S., Vincelette, N.D., Green, M.R., Wahner Hendrickson, A.E., Abraham, I., Targeting immune checkpoints in unresectable metastatic cutaneous melanoma: a systematic review and meta-analysis of anti-CTLA-4 and anti-PD-1 agents trials. Cancer Med., 2016.
2. [2] Hodi, F.S., O'Day, S.J., McDermott, D.F., Weber, R.W., Sosman, J.A., Haanen, J.B., et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363:8 (2010), 711–723.
3. [3] Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D.R., Steins, M., Ready, N.E., et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N. Engl. J. Med. 373:17 (2015), 1627–1639.
4. [4] Brahmer, J., Reckamp, K.L., Baas, P., Crinò, L., Eberhardt, W.E.E., Poddubskaya, E., et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. New Engl. J. Med. 373:2 (2015), 123–135.
5. [5] Kourie, H.R., Awada, G., Awada, A.H., Rare side-effects of checkpoint inhibitors. Curr. Opin. Oncol., 2016.
6. [6] Andres, E., Maloisel, F., Idiosyncratic drug-induced agranulocytosis or acute neutropenia. Curr. Opin. Hematol. 15:1 (2008), 15–21.
7. ®-induced neutropenia resolution without the use of granulocyte colony-stimulating factor. South Med. J. 103:11 (2010), 1167–1169.
8. [8] Frattini, F., Crestani, S., Vescovi, P.P., Franchini, M., Pure white cell aplasia induced by mesalazine in a patient with ulcerative colitis. Hematology 18:3 (2013), 181–182.
9. [9] Weber, J.S., Dummer, R., de Pril, V., Lebbe, C., Hodi, F.S., Patterns of onset and resolution of immune-related adverse events of special interest with ipilimumab: detailed safety analysis from a phase 3 trial in patients with advanced melanoma. Cancer 119:9 (2013), 1675–1682.
10. [10] Weber, J.S., Antonia, S.J., Topalian, S.L., Schadendorf, D., Larkin, J.M., Sznol, M., et al. Safety Profile of Nivolumab (NIVO) in Patients (pts) with Advanced Melanoma (MEL): A Pooled Analysis, ASCO Annual Meeting Proceedings, 2015 (editors).
11. [11] Hamid, O., Robert, C., Daud, A., Hodi, F.S., Hwu, W.J., Kefford, R., et al. Safety and tumor responses with lambrolizumab (anti–PD-1) in melanoma. New Engl. J. Med. 369:2 (2013), 134–144.
12. [12] Topalian, S.L., Sznol, M., McDermott, D.F., Kluger, H.M., Carvajal, R.D., Sharfman, W.H., et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J. Clin. Oncol. 32:10 (2014), 1020–1030.
13. [13] Akhtari, M., Waller, E.K., Jaye, D.L., Lawson, D.H., Ibrahim, R., Papadopoulos, N.E., et al. Neutropenia in a patient treated with ipilimumab (anti-CTLA-4 antibody). J. Immunother. 32:3 (2009), 322–324 (Hagerstown, Md: 1997).
14. [14] Quirk, S.K., Shure, A.K., Agrawal, D.K., Immune-mediated adverse events of anticytotoxic T lymphocyte-associated antigen 4 antibody therapy in metastatic melanoma. Transl. Res. 166:5 (2015), 412–424.
15. [15] Romo-Tena, J., Gómez-Martín, D., Alcocer-Varela, J., CTLA-4 and autoimmunity: new insights into the dual regulator of tolerance. Autoimmun. Rev., 12(12), 2013, 1171.
16. [16] Siwiec, A., Majdan, M., [The role of the PD-1 protein in pathogenesis of autoimmune diseases, with particular consideration of rheumatoid arthritis and systemic lupus erythematosus]. Postepy higieny i medycyny doswiadczalnej (Online) 69 (2015), 534–542.
17. [17] Johnson, D.B., Sullivan, R.J., Ott, P.A., Carlino, M.S., Khushalani, N.I., Ye, F., et al. Ipilimumab therapy in patients with advanced melanoma and preexisting autoimmune disorders. JAMA Oncol. 2:2 (2016), 234–240.
18. [18] Fay, A.P., Moreira, R.B., Nunes Filho, P.R., Albuquerque, C., Barrios, C.H., The management of immune-related adverse events associated with immune checkpoint blockade. Expert Rev. Qual. Life Cancer Care 1:1 (2016), 89–97.
19. [19] Horvat, T.Z., Adel, N.G., Dang, T.O., Momtaz, P., Postow, M.A., Callahan, M.K., et al. Immune-Related adverse events, need for systemic immunosuppression, and effects on survival and time to treatment failure in patients with melanoma treated with ipilimumab at memorial sloan kettering cancer center. J. Clin. Oncol. 33:28 (2015), 3193–3198.